Trial Profile
A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 10 Aug 2023 Planned End Date changed from 1 May 2022 to 1 Dec 2023.
- 10 Aug 2023 Planned primary completion date changed from 1 May 2022 to 1 Dec 2023.
- 04 Jun 2023 According to a Puma Biotechnology media release, results of this trial were published by Joyce O'Shaughnessy et al. (Jama Network Open, April 2021).